Kayla Hoang Nguyen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kayla Hoang Nguyen has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ferdinando Pucci
Ba Department of Cell, Developmental and Cancer Biology, Oregon Health and Science University, Portland, OR, USA
1 shared publication Joaquim Seras-Franzoso
Drug Delivery and Targeting Group, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
1 shared publication- Naoki Oshimori
Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, OR 97239, USA; Department of Dermatology, Oregon Health and Science University, Portland, OR 97239, USA; Department of Otolaryngology, Head & Neck Surgery, Oregon Health and Science University, Portland, OR 97239, USA; Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA
1 shared publication - Natalie Claudio
Department of Otolaryngology – Head and Neck Surgery, Oregon Health & Science University, Portland, Oregon
1 shared publication - Patricia González-Callejo
CIC biomaGUNE, Basque Research and Technology Alliance (BRTA)
1 shared publication - Tahereh Ziglari
Department of Otolaryngology – Head and Neck Surgery, Oregon Health and Science University, Portland, Oregon
1 shared publication
Latest Publications
- Open Access
- 3 February 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (2) , e0279400
Cancer stem cell-derived extracellular vesicles preferentially target MHC-II–macrophages and PD1+ T cells in the tumor microenvironment
Immunotherapy is an approved treatment option for head and neck squamous cell carcinoma (HNSCC). However, the response rate to immune checkpoint blockade is only 13% for recurrent HNSCC, highlighting the urgent need to better understand tumor-immune interplay, with the ultimate goal of improving patient outcomes. HNSCC present high local recurrence rates and therapy resistance that can be attributed to the presence of cancer stem cells (CSC) within tumors. CSC exhibit singular properties that enable them to avoid immune detection and eradication. How CSC communicate with immune cells and which immune cell types are preferentially found within the CSC niche are still open questions. Here, we used genetic approaches to specifically label CSC-derived extracellular vesicles (EVs) and to perform Sortase-mediated in vivo proximity labeling of CSC niche cells. We identified specific immune cell subsets that were selectively targeted by EVCSC and that were found in the CSC niche. Native EVCSC preferentially targeted MHC-II–macrophages and PD1+ T cells in the tumor microenvironment, which were the same immune cell subsets enriched within the CSC niche. These observations indicate that the use of genetic technologies able to track EVs without in vitro isolation are a valuable tool to unveil the biology of native EVCSC.
- 3 February 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (2) , e0279400
Open AccessCancer stem cell-derived extracellular vesicles preferentially target MHC-II–macrophages and PD1+ T cells in the tumor microenvironment
Immunotherapy is an approved treatment option for head and neck squamous cell carcinoma (HNSCC). However, the response rate to immune checkpoint blockade is only 13% for recurrent HNSCC, highlighting the urgent need to better understand tumor-immune interplay, with the ultimate goal of improving patient outcomes. HNSCC present high local recurrence rates and therapy resistance that can be attributed to the presence of cancer stem cells (CSC) within tumors. CSC exhibit singular properties that enable them to avoid immune detection and eradication. How CSC communicate with immune cells and which immune cell types are preferentially found within the CSC niche are still open questions. Here, we used genetic approaches to specifically label CSC-derived extracellular vesicles (EVs) and to perform Sortase-mediated in vivo proximity labeling of CSC niche cells. We identified specific immune cell subsets that were selectively targeted by EVCSC and that were found in the CSC niche. Native EVCSC preferentially targeted MHC-II–macrophages and PD1+ T cells in the tumor microenvironment, which were the same immune cell subsets enriched within the CSC niche. These observations indicate that the use of genetic technologies able to track EVs without in vitro isolation are a valuable tool to unveil the biology of native EVCSC.